A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
The purpose of this study is to test how vinflunine interacts with rifampin in the human body
Cancer
DRUG: Vinflunine|DRUG: Rifampin
The Primary Outcome Measure of the effect of rifampin on the pharmacokinetics (PK) of intravenous (IV) vinflunine will be determined from the PK measurements, taken during Cycle 2 of study treatment, at approximately 4 weeks after the start of study treatment
The Secondary Outcome Measures of the safety and tolerability of vinflunine when administered alone and with rifampin, determined after 2 complete 21-day Cycles of study treatment, at approximately 6 weeks after the start of study treatment
The purpose of this study is to test how vinflunine interacts with rifampin in the human body